Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fonakizumab for active psoriatic arthritis (single-arm, multicenter Phase 4 study)
ChiCTR2500113850Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fonakizumab in psoriatic arthritis (PsA), sponsored by Qilu Hospital of Shandong University. Primary endpoint: ACR20 response at week 16. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
fonakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ChiCTR2500113850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113850.